Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Following the loss or removal of ewes' lambs, ewes frequently continue to lactate for a short time, which potentially predisposes them to mastitis. Therapies that stop or reduce milk production in such situations would be beneficial. Milk production in ruminants is positively correlated with serum concentrations of
growth hormone
(GH). We sought to determine whether methscopolamine bromide (MB), an anticholinergic agent reported to block GH secretion, would selectively and reversibly reduce milk yield in lactating ewes. White-face ewes (n = 24) that were nursing lambs were assigned on d 59 +/- 2 postpartum (d 0) to receive s.c. injections of 96 mg of MB on d 2, 3, and 4 (1630). On d 0, 2, 5, and 7 (0900), ewes were sequentially separated from their lambs, treated with 40 IU
oxytocin
, and 30 s later were milked. Ewes remained separated from their lambs for 6 h, after which (1500) ewes were again milked and quantity of milk was determined. Milk yields at d 0, 2, 5, and 7 were 267 +/- 16.9, 266 +/- 15.5, 225 +/- 11.9, and 244 +/- 13.4 g, respectively. It was concluded that treatment of ewes with MB reduced milk yield (P < .01), and the effect was reversible. A second experiment was performed to determine the acute effects of MB on serum concentrations of GH. Hampshire ewes (n = 14) that were nursing lambs were assigned on d 55 +/- 1 postpartum to receive a.s.c. injection of saline (n = 7) or 96 mg of MB (n = 7) at min 0.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:A potential strategy for decreasing milk production in the ewe at weaning using a growth hormone release blocker. 759 71
The effects of
growth hormone
(GH) and prolactin (PRL) (1, 10, 100, 1000 or 10,000 ng/ml medium) on
oxytocin
, vasopressin, progesterone, cAMP and cGMP release by cultured bovine granulosa cells were studied. It was found that GH significantly stimulated
oxytocin
, vasopressin and cAMP but suppressed progesterone secretion. PRL tended to have the same pattern of action on nonapeptide, cAMP and steroid release, but its effect was not as great, with only a high supraphysiological dose (10,000 ng/ml) producing a statistically significant effect. No significant influence of GH on cGMP output was observed. Physiological doses of PRL (1, 10, 100 or 1000 ng/ml) significantly inhibited cGMP production whilst a high dose (10,000 ng/ml) resulted in stimulation. These observations suggested that GH may regulate ovarian
oxytocin
, vasopressin, progesterone and cAMP secretion. The effects of PRL on the release of these substances appeared to be non-specific, possibly resulting from its structural similarity to GH.
...
PMID:Growth hormone and prolactin affect oxytocin, vasopressin, progesterone and cyclic nucleotide secretion by bovine granulosa cells in vitro. 783 85
Because of the enormous growth over the last three decades of research on the role of peptides in the brain, the need became apparent to determine the status of these compounds in terms of their current research interest. Since 1965, over a quarter of a million research papers have been published on peptides that have since been classified as neuroactive. The present study was undertaken to analyze systematically the yearly trends of research emphasis in neuroactive peptides as reflected by their individual frequency of publication by year, beginning in 1966. A computer analysis of the publication characteristics was carried out using the Medline data base in which the citation search was limited to the topic brain crossed with the topic mammal. One criterion for the inclusion of a given peptide in the analysis was a frequency of 25 or more citations following its discovery, as related to the mammalian brain. The 42 peptides that met this criterion were: adrenocorticotropic hormone, angiotensin II, atrial natriuretic factor, bombesin, bradykinin, calcitonin, calcitonin gene-related peptide, carnosine, beta-casomorphin, cholecystokinin, corticotropin-releasing factor, delta sleep-inducing peptide, dynorphin, beta-endorphin, Leu-enkephalin, Met-enkephalin, galanin, gastrin, glucagon,
growth hormone
, growth hormone-releasing factor, insulin, kyotorphin, beta-lipotropin, luteinizing hormone-releasing factor, melanocyte-stimulating hormone release inhibitory factor-1, alpha-melanocyte-stimulating hormone, motilin, neurokinin A, neurokinin B, neuropeptide Y, neurotensin,
oxytocin
, pituitary adenylate cyclase activating polypeptide, peptide HI, prolactin, secretin, somatostatin, substance P, thyroid-releasing hormone, vasopressin, and vasoactive intestinal peptide. An overall analysis of the 298,105 papers published on these 42 peptides since 1965 revealed that the research activity of 24,742, or 8.30%, of the studies, focused on their neuroactive properties. Taken as a whole, the research on neuroactive peptides reached a peak in 1986, as reflected by the total of 1793 papers published during that year. Although the level of publication has fluctuated between 1548 and 1774 research papers over the last 6 years, it is now clear that the trend in research on neuroactive peptides has reached an asymptote today that shows no sign of deviation. A temporal analysis year by year of individual publication profiles revealed three distinct trends: 1) peptides showed a slow development in research interest and did not exceed more than 15-30 publications per year; 2) peptides exhibited a steady increase in research activity over the years that continues today; and 3) peptides displayed an initial, often intense, research emphasis that inexplicably declined, in some cases precipitously, in the mid 1980s.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Neuroactive peptides: unique phases in research on mammalian brain over three decades. 800 41
Nitric oxide (NO), previously identified with endothelium derived relaxing factor (EDRF), is thought to play a role in central neurotransmission: it is characterized by high lipid solubility and short half life, and NO-synthase, the enzyme which generates NO from L-arginine, has been found in the central nervous system (CNS), both in neuronal and glial cells. NO is believed to be involved in many neural events, such as neurotoxicity from N-methyl-D-aspartate (NMDA) receptor overstimulation, brain damage from vascular stroke, fever, nociception, memory and appetite control. Recent evidence implicates NO as a modulator of endocrine secretions, with inhibition of insulin,
growth hormone
(GH) and
oxytocin
release and stimulation of vasopressin (AVP), adrenocorticotropin (ACTH) and corticotropin releasing hormone (CRH) release. NO and prostaglandins could mediate neuroendocrine activities of cytokines such as interleukin-1 (IL-1) and interleukin-2 (IL-2), particularly in the CNS.
...
PMID:Nitric oxide: a gas as a modulator of neuroendocrine secretions. 818 Dec 9
To evaluate the significance of endogenous vasopressin and
oxytocin
in control of anterior pituitary hormone release, antiserum against vasopressin (AB-VP) or
oxytocin
(AB-OT) were microinjected into the third ventricle (3V) of conscious, ovariectomized rats to immunoneutralize endogenous VP or OT, respectively. Blood samples were collected just before and at different times after the microinjections. There were no differences in the plasma LH, FSH, PRL and TSH concentrations between control groups injected into the 3V with normal rabbit serum (NRS) and groups submitted to the intraventricular injection of AB-OT or AB-VP for 24 h after the injections. Plasma
growth hormone
(GH) declined significantly by 4 h after NRS injection, remained low at 6 h and had rebounded to nearly initial levels at 24 h. This pattern was not changed by microinjection of AB-VP, but plasma GH increased significantly compared to initial values in the period from 1 to 24 h after intraventricular microinjection of AB-OT. The intraventricular injection of AB-VP or AB-OT significantly decreased plasma ACTH; however, the effect of AB-VP was more prolonged and persisted for 6 rather than 4 h after injection. Thus, endogenous
oxytocin
may play a role in the control of basal GH release probably by stimulating somatostatin secretion and/or inhibiting GH-releasing hormone secretion or by both actions. On the other hand, both endogenous vasopressin and
oxytocin
play a physiologically significant stimulatory role in the control of basal ACTH release.
...
PMID:Actions of endogenous vasopressin and oxytocin on anterior pituitary hormone secretion. 839 22
Groups of 9 or 10 cows were assigned to one of three treatments 1) machine-milking three times daily, 2) machine-milking six times daily, and 3) suckling three times daily in addition to machine- milking three times daily. Treatments were conducted during the first 6 wk postpartum; thereafter, all cows were milked three times daily. During treatment, milk production was highest for suckled cows and lowest for cows milked three times daily. The DMI were similar for suckled cows and cows milked three times daily but higher for those milked six times daily. Body weight loss was greatest for suckled cows and least for cows milked three times daily. During wk 7 to 18 postpartum, cows milked six times daily exhibited a carry-over effect on milk production that was greater than that of other groups, During treatment, plasma
growth hormone
and IGF-I concentrations were elevated for suckled cows and, to a lesser extent, for cows milked six times daily. Prolactin and
oxytocin
similarly increased, but insulin decreased in suckled cows and, to a lesser extent, in cows milked six times daily. Posttreatment differences persisted for insulin and IGF-I, but not for the other hormones. Increased frequency of udder emptying increased milk production, and suckling was superior to machine-milking. High milk production was associated with elevated
growth hormone
, IGF-I, prolactin, and
oxytocin
, although cause and effect could not be established. The failure of suckled cows to increase feed intake to match output requires further investigation.
...
PMID:Relationship between frequent milking or suckling in early lactation and milk production of high producing dairy cows. 867 55
Neuroendocrine response to stress stimuli is aimed to maintain body homeostasis. The activation of the neuroendocrine system is accomplished mainly by two ways: by feedback regulation based on the recognition of altered metabolic homeostasis by appropriate receptors sending the signal into the CNS, and by forward regulation involving a direct stimulation of the neuroendocrine system by a central command coming from an activated brain regulatory center. With regard to mechanisms of neuroendocrine activation, the signal specificity and site of its origin are of particular importance. The significance of the signal in neuroendocrine responses has been evaluated in three different stress conditions: hypoglycemia, surgical trauma and dynamic physical exercise. The stimulus inducing neuroendocrine response during hypoglycemia is the glucopenia. The signal for the activation of the neuroendocrine response is generated in glucosensitive cells which are not located in a single brain structure (hypothetical glucostat). The signal for
growth hormone
, vasopressin and
oxytocin
release is produced in brain structures protected by the blood-brain barrier, that for ACTH release in regions both protected and unprotected by the barrier, while the signal for prolactin release is generated in tissues lacking the blood-brain barrier. The neuroendocrine response during surgical trauma is activated by a signal formed in the damaged tissue reaching the CNS by neural pathways. Moreover, cytokins may participate on endocrine stimulation in those surgical interventions in which a large amount of bacterial endotoxins is released. During a complicated surgery, e.g. during a bypass other signals and modifying factors, such as hypothermia, dilution of blood, hypoperfusion of organs, rewarming of the body and hormone degradation in the oxygenator are important. On the On the other hand, during a short-term dynamic exercise, a forward regulation by a central signal from the activated CNS motor center comes into play with the consequent release of catecholamines,
growth hormone
, etc. In the control of some other hormones (beta-endorphin, partly ACTH) and especially during a long term exercise, neural signals from working muscles (feedback) are also involved. During a static exercise mainly catecholamines triggered by signals from working muscle cells are activated. The understanding of the signal and mechanisms of neuroendocrine activation during stress is indispensable for selective modulation of physiological and pathological responses.
...
PMID:[Activation of the neuroendocrine system during changes in homeostasis during stress conditions]. 868 9
The aim of the present experiments was to demonstrate the release of insulin-like growth factor-I (IGF-I) by human granulosa cells, and to examine the role of
growth hormone
(GH),
oxytocin
, steroids and cAMP-dependent intracellular mechanism in its control. A significant accumulation of IGF-I in a serum-supplemented medium in which the human granulosa cells were cultured for 4 days was observed. The concentration of IGF-I in the medium was particularly high at 3 and 4 days of culture. The addition of GH (1-10,000 ng/ml) to the medium increased IGF-I secretion by the cells. A higher GH dose (100,000 ng/ml) was inhibitory.
Oxytocin
stimulated IGF-I release at doses of 10-10,000 ng/ml. Dibutyryl-cAMP, isobutyl-methyl-xanthine (inhibitor of cAMP catabolism) or forskolin (stimulator of cAMP production) inhibited IGF-I output at these doses. Additions of progesterone (1-1,000 ng/ml) did not affect IGF-I release, whilst adrostenedione and estradiol were stimulatory at doses of 1, 10, 100, 1,000 ng/ml and 10, 100 and 1,000 ng/ml respectively. Testosterone inhibited IGF-I at a dose of 1,000 ng/ml but not at lower doses (1, 10 or 100 ng/ml). Blockade of estradiol (but not of testosterone) in the medium by specific antisera (1 or 10%) significantly reduced IGF-I output. The same effect was observed with an antiserum to progesterone when added at 0.1%, whilst higher doses (1 or 10%) stimulated IGF-I secretion. The present observations demonstrate the involvement of peptide, steroid hormones and cAMP in the regulation of IGF-I secretion by luteinized human granulosa cells. In particular, both GH and
oxytocin
are stimulators of IGF-I release. Estradiol and androstenedione, but not testosterone, may also be stimulators of IGF-I output. The involvement of progesterone in this process can also not be excluded. A cAMP-dependent intracellular mechanism appears to play an inhibitory role in the regulation of IGF-I secretion by luteinized human granulosa cells.
...
PMID:The release of insulin-like growth factor-I by luteinized human granulosa cells in vitro: regulation by growth hormone, oxytocin, steroids and cAMP-dependent intracellular mechanisms. 878 8
Endothelins (ETs) were initially thought to be primarily involved in the control of cardiovascular activity, but the presence of ETs and their receptors in a wide variety of other tissues has suggested a much broader range of functions. Specific receptors for ETs are found in nonvascular tissues including neuronal, neuroendocrine, and endocrine cells. In addition, immunoreactive ETs are present in the brain, pituitary, and peripheral endocrine tissues. However, the ET levels in hypothalamo-hypophysial portal and peripheral blood are low, suggesting that the ET system participates in neuroendocrine regulation through paracrine and/or autocrine mechanisms. Both ETA and ETB receptors are expressed in the hypothalamus, adrenal, parathyroid glands, pancreas, ovary, uterus, placenta, and prostate, while only ETA receptors are expressed in GT1 neurons, anterior pituitary cells, alpha T3-1 immortalized gonadotropes, parathyroid-derived cells, thyrocytes, testicular Leydig and Sertoli cells, normal and neoplastic ovarian granulosa cells, chondrocytes, and other cell types. Activation of ET receptors elicits the sequence of cellular events typical of Ca(2+)-mobilizing receptors, with prominent increases in phosphoinositide hydrolysis and elevations of [Ca2+]i that occur in oscillatory and nonoscillatory modes depending on the cell type. ET-induced activation of the phosphoinositide/Ca(2+)- mobilizing pathway in neuronal and endocrine cells is associated with rapid stimulation of secretory responses, including release of gonadotropin-releasing hormone,
oxytocin
, vasopressin, substance P, atrial natriuretic peptides, gonadotropins, thyrotropin,
growth hormone
, parathyroid hormone, aldosterone, and catecholamines. On the other hand, ET has inhibitory actions on prolactin, progesterone, and renin release. In addition to stimulating phospholipase C-dependent pathways, ETs also activate phospholipase D-and MAP-kinase-dependent pathways in some of their target cells, as well as expression of early response genes and increased mitogenic activity. In many neuroendocrine cells, ET induces rapid and marked desensitization of its signaling system, in association with extensive internalization of ET receptors and reduced signaling and secretory responses. These findings raise the possibility that ETs participate in the control of secretory responses in the hypothalamo-pituitary system and peripheral endocrine cells, as well as in long-term aspects of regulation in certain neuroendocrine cells.
...
PMID:Expression and signal transduction pathways of endothelin receptors in neuroendocrine cells. 881 99
The influence of
growth hormone
(GH) (10-10,000 ng/ml medium) on the endocrine and generative functions of cultured bovine ovarian cells was studied. The release of estardiol,
oxytocin
, vasopressin by granulosa cells, as well as the nuclear maturation of oocytes ant their subsequent cleavage after in vitro fertilisation were analysed. GH stimulated the release of estradiol,
oxytocin
and vasopressin in a dose-dependent manner. The GH treatments during oocyte in vitro maturation had no marked influence on meiosis reinitiation, but significantly delayed its completion in a dose-dependent manner. These GH additions however did not change the ability of oocytes to cleave after in vitro fertilisation. Thus, GH may be a potent regulator of both the endocrine and generative functions of bovine ovarian cells.
...
PMID:Direct action of growth hormone on bovine ovarian cells: effects on estradiol, oxytocin, vasopressin release by granulosa cells and on oocyte maturation and cleavage in vitro. 894 18
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>